DASTY News and Press, Dassault Systemes Sa Adr From 04/27/22

The following slide deck was published by Dassault Systèmes SE in conjunction with their 2022 Q1 earnings call. For further details see: Dassault Systèmes SE 2022 Q1 - Results - Earnings Call Presentation

Dassault Systemes press release (OTCPK:DASTY): Q1 Non-GAAP EPS of €0.27. Revenue of €1.32B (+12.8% Y/Y). FY2022 non-IFRS objectives: reaffirming total revenue growth of 9%-10%, in constant currencies (consensus growth of 5.2% Y/Y). Raising non-IFRS diluted EPS tar...

ADP,ALKS,AMT,APH,BA,BG,BSX,BXMT,CHEF,CHKP,CME,CS,CSTM,CVE,DAN,OTCPK:DASTY,DB,OTCPK:DDAIF,DX,EEFT,ETR,EVR,EXTR,FISV,GD,GIB,GPI,GRMN,GSK,HEES,HELE,HES,HESM,HOG,HUM,IART,OTCPK:IBDSF,IQV,KHC,LPL,MAS,MHO,MKL,NEO,NSC,NYCB,OC,ODFL,OSK,PAG,PB,R,RES,RGEN,ROL,SABR,SF,SHOO,SLAB,SLDB,SLGN,SPOT,STM,STX,TD...

ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A sharp spike in bond yields pressured growth stocks and ...

Palantir Technologies has exhibited tremendous growth in recent years and management expects that trend to continue. Palantir's cash flows are now robust and this is encouraging, and this should also continue to be the case moving forward. But PLTR stock is pricey for value-orient...

Plus Therapeutics (NASDAQ:PSTV) said it had expanded its partnership with Medidata, a unit of Dassault Systèmes (OTCPK:DASTY), to speed enrollment and reduce clinical trial costs of its Phase 2 trial of Rhenium-186 NanoLiposome in recurrent glioblastoma.  The par...

Dassault Aviation (OTCPK:DASTY) CEO Eric Trappier threatens to pull out of developing a European fighter jet with Airbus (OTCPK:EADSF, OTCPK:EADSY), the latest in a lengthy dispute over leadership of the project. The New Generation Fighter project was first agreed by the French and German gov...

Plus Therapeutics (PSTV) is collaborating with Medidata, a unit of Dassault Systèmes (OTCPK:DASTY), to evaluate the use of its Synthetic Control Arm (SCA) solution in a planned phase 2 trial of Rhenium-186 NanoLiposome in recurrent glioblastoma, a type of brain cancer. The...

Dassault Systemes SE (DASTY) Q4 2021 Earnings Conference Call February 03, 2022, 09:00 ET Company Participants François-José Bordonado - VP, IR Bernard Charles - Vice Chairman & CEO Tarek Sherif - Chairman, Dassault Systemes Life Sciences & Healthcare Pascal Daloz - COO, CFO...

The following slide deck was published by Dassault Systèmes SE in conjunction with their 2021 Q4 earnings call. For further details see: Dassault Systèmes SE 2021 Q4 - Results - Earnings Call Presentation